Cellceutix Confident in Its Formidable Antibiotic Arsenal

World Health Organization Last Week Reported That Antibiotic Resistance Is Now a Major Threat to Public Health Across the Entire Planet

BEVERLY, MA--(Marketwired - May 12, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report this update on its clinical trial of Brilacidin™ for Acute Bacterial Skin and Skin Structure Infections (ABSSSI).

The phase 2b ABSSSI trial, comparing 1- and 3-day regimens of Brilacidin to a standard 7-day regimen of daptomycin, continues to enroll at the projected pace and we expect to reach the 50 percent enrollment this week. Thus far no treatment-related serious adverse events (SAE) have been reported. A more comprehensive analysis on this double blinded study will be forthcoming as soon as the information is made available to us.

"As we are advancing in this ABSSSI trial, our acquisition of Brilacidin is confirming our initial assessments and expectations of the compound," commented Leo Ehrlich, Chief Executive Officer at Cellceutix. "We are well on our way towards fruition of our goals set for this drug. Between the progress in the ABSSSI trial and our recently announced studies in gram-negative infections, we have greater confidence that Cellceutix now has one of the most formidable arsenals of antibiotic compounds in all of pharma, whether big or small."

About Cellceutix: Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is planning a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention and treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound, has shown in the laboratory to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol is presently in a bioequivalence crossover clinical trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's key antibiotic, Brilacidin, is in a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Brilacidin has the potential to be a single-dose therapy or a dosing regimen that is shorter than currently marketed antibiotics for multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com.

Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Cellceutix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Cellceutix has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Cellceutix's need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that Cellceutix's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in Cellceutix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

INVESTOR AND MEDIA CONTACT: Cellceutix Corporation Leo Ehrlich (978) 236-8717 Email Contact

Innovation Pharmaceuticals (CE) (USOTC:IPIX)
Historical Stock Chart
From Mar 2024 to Apr 2024